Bambusa Therapeutics Inc(BBTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 4:06 PM ET (Korea 11/3 06:06)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 50.9M | Perf Week | - |
| Market Cap | 0.80B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | - |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 96.33% | Short Float | - | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | - | Perf YTD | 7.53% |
| Book/sh | - | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | 2.17% ($15.66) | Perf Year | - |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 17.65% ($13.60) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.65 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | - | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | 3.26% ($15.49) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | 3.26% ($15.49) | Rel Volume | 0.2 | Prev Close | $14.99 |
| Employees | 26 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | 3.26% ($15.49) | Avg Volume(3M) | 2.20M | Price | $16 |
| IPO | 2026/10/30 | Option/Short | No/Yes | Trades | 2352 | Volume | 433,210 | Change | 6.74% |
BBTXBambusa Therapeutics Inc | NASD | Biotechnology 🧬 Bambusa Therapeutics is a clinical-stage biotechnology company based in Boston, USA, developing long-acting precision bispecific antibodies targeting immune and inflammatory diseases. Established in 2024, this startup possesses pipelines for inflammatory skin diseases and respiratory diseases, and has recently secured clinical development funds through its Nasdaq listing.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 20% of its average volume.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 96.3%.
Tap to view numbers
It ranks #174 of 597 in the industry
Based on market cap of $796M.
CRVS#171 Corvus Pharmaceuticals Inc $816M PER - 
AKTS#172 Aktis Oncology Inc $811M PER - 
PRME#173 Prime Medicine Inc $805M PER - BBTX#174 Bambusa Therapeutics Inc $796M PER - 
ABUS#175 Arbutus Biopharma Corp $792M PER 5.1 
FAQ
What kind of company is BBTX?
BBTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BBTX?
The market cap of BBTX is approximately $796M, ranking 2,752 within its sector.
What is the 52-week high and low for BBTX?
BBTX has recorded a 52-week high of $15.66 and a low of $13.60.
